Targeted Deprescribing in an Outpatient Hemodialysis Unit: A Quality Improvement Study to Decrease Polypharmacy

Background Polypharmacy in hemodialysis patients can result in adverse patient outcomes. Deprescribing tools can reduce polypharmacy, yet no method exists for an outpatient hemodialysis population. Design Quality improvement study. Setting & Participants 240 patients in a tertiary-care outpatien...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:American journal of kidney diseases 2017-11, Vol.70 (5), p.611-618
Hauptverfasser: McIntyre, Caitlin, Pharm D, McQuillan, Rory, MD, MSc, Bell, Chaim, MD, PhD, Battistella, Marisa, Pharm D
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 618
container_issue 5
container_start_page 611
container_title American journal of kidney diseases
container_volume 70
creator McIntyre, Caitlin, Pharm D
McQuillan, Rory, MD, MSc
Bell, Chaim, MD, PhD
Battistella, Marisa, Pharm D
description Background Polypharmacy in hemodialysis patients can result in adverse patient outcomes. Deprescribing tools can reduce polypharmacy, yet no method exists for an outpatient hemodialysis population. Design Quality improvement study. Setting & Participants 240 patients in a tertiary-care outpatient hemodialysis unit. Quality Improvement Plan We aimed to: (1) develop a deprescribing tool for target medications with poor evidence for efficacy and safety, (2) determine its effectiveness in decreasing polypharmacy, and (3) monitor patient safety and satisfaction. Outcomes The primary outcome was the proportion of target medications completely deprescribed after 4 weeks. Secondary outcomes were the proportion of target medications completely deprescribed after 6 months, average number of medications per patient before and after deprescription, and proportion of successful deprescriptions for each target medication. Measurements Number of medications deprescribed at 4 weeks and 6 months. Patient safety and satisfaction were monitored using drug-specific monitoring parameters. Results A deprescribing tool for specific medications was developed and implemented in the hemodialysis unit. 5 medication classes were selected: quinine, diuretics, α1 -blockers, proton pump inhibitors, and 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins). All 240 patients in the unit were screened using the deprescribing tool. There were 171 of 240 (71%) patients prescribed at least 1 of the 5 target medications, and after applying the tool, 35 of 40 (88%) eligible patients had the medications deprescribed. There were 31 of 40 (78%) target medications completely deprescribed. 6 months after the study, only 5 of 31 (16%) medications discontinued were represcribed. At the end of the study, 57% of patients were taking fewer medications than at baseline. No adverse events were observed. Limitations Single-center study that relied on patient self-reporting of medication use and adherence to our recommendations. Conclusions Deprescribing tools can be applied successfully in an outpatient hemodialysis unit to reduce polypharmacy while maintaining patient safety and satisfaction.
doi_str_mv 10.1053/j.ajkd.2017.02.374
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1889386098</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0272638617305826</els_id><sourcerecordid>1889386098</sourcerecordid><originalsourceid>FETCH-LOGICAL-c477t-10a335b59da63bafc4ebc345cf646c169a486ad6af62ab1257587e502c69f9f73</originalsourceid><addsrcrecordid>eNp9kctu1TAQhi0EoofCC7BAXrJJ8CVxHISQqnJppUoFtV1bE2dSfJpbbadS3oZn4clwdAoLFqw8i-__Nf6GkNec5ZyV8t0-h_1dmwvGq5yJXFbFE7LjpZCZ0lI_JTsmKpEpqdUReRHCnjFWS6WekyOhC66k4DsyX4O_xYgt_YSzx2C9a9x4S91IYaSXS5whOhwjPcNhah30a3CB3owuvqcnv35-X6B3caXnw-ynBxw28iou7UrjlBqtRwhIv039Ov8AP4BdX5JnHfQBXz2-x-Tmy-fr07Ps4vLr-enJRWaLqooZZyBl2ZR1C0o20NkCGyuL0naqUJarGgqtoFXQKQENF2VV6gpLJqyqu7qr5DF5e-hNi90vGKIZXLDY9zDitATDta6TGVbrhIoDav0UgsfOzN4N4FfDmdlMm73ZTJvNtGHCJNMp9Oaxf2kGbP9G_qhNwIcDgOmXDw69CTaZtNg6jzaadnL_7__4T9z2bnQW-jtcMeynxY_Jn-EmCMPM1Xbr7dS8kqzUafwNBlGmdw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1889386098</pqid></control><display><type>article</type><title>Targeted Deprescribing in an Outpatient Hemodialysis Unit: A Quality Improvement Study to Decrease Polypharmacy</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>McIntyre, Caitlin, Pharm D ; McQuillan, Rory, MD, MSc ; Bell, Chaim, MD, PhD ; Battistella, Marisa, Pharm D</creator><creatorcontrib>McIntyre, Caitlin, Pharm D ; McQuillan, Rory, MD, MSc ; Bell, Chaim, MD, PhD ; Battistella, Marisa, Pharm D</creatorcontrib><description>Background Polypharmacy in hemodialysis patients can result in adverse patient outcomes. Deprescribing tools can reduce polypharmacy, yet no method exists for an outpatient hemodialysis population. Design Quality improvement study. Setting &amp; Participants 240 patients in a tertiary-care outpatient hemodialysis unit. Quality Improvement Plan We aimed to: (1) develop a deprescribing tool for target medications with poor evidence for efficacy and safety, (2) determine its effectiveness in decreasing polypharmacy, and (3) monitor patient safety and satisfaction. Outcomes The primary outcome was the proportion of target medications completely deprescribed after 4 weeks. Secondary outcomes were the proportion of target medications completely deprescribed after 6 months, average number of medications per patient before and after deprescription, and proportion of successful deprescriptions for each target medication. Measurements Number of medications deprescribed at 4 weeks and 6 months. Patient safety and satisfaction were monitored using drug-specific monitoring parameters. Results A deprescribing tool for specific medications was developed and implemented in the hemodialysis unit. 5 medication classes were selected: quinine, diuretics, α1 -blockers, proton pump inhibitors, and 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins). All 240 patients in the unit were screened using the deprescribing tool. There were 171 of 240 (71%) patients prescribed at least 1 of the 5 target medications, and after applying the tool, 35 of 40 (88%) eligible patients had the medications deprescribed. There were 31 of 40 (78%) target medications completely deprescribed. 6 months after the study, only 5 of 31 (16%) medications discontinued were represcribed. At the end of the study, 57% of patients were taking fewer medications than at baseline. No adverse events were observed. Limitations Single-center study that relied on patient self-reporting of medication use and adherence to our recommendations. Conclusions Deprescribing tools can be applied successfully in an outpatient hemodialysis unit to reduce polypharmacy while maintaining patient safety and satisfaction.</description><identifier>ISSN: 0272-6386</identifier><identifier>EISSN: 1523-6838</identifier><identifier>DOI: 10.1053/j.ajkd.2017.02.374</identifier><identifier>PMID: 28416321</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Adrenergic alpha-Antagonists - therapeutic use ; Adult ; Aged ; Aged, 80 and over ; Ambulatory Care ; Deprescribing ; Deprescriptions ; Diuretics - therapeutic use ; elderly ; end-stage renal disease (ESRD) ; Female ; hemodialysis (HD) ; Hemodialysis Units, Hospital ; Humans ; Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use ; Kidney Failure, Chronic - therapy ; Male ; medication optimization ; medication prescribing patterns ; Middle Aged ; Muscle Relaxants, Central - therapeutic use ; Nephrology ; Ontario ; outpatient HD ; patient safety ; pill burden ; Polypharmacy ; potentially inappropriate medications ; Proton Pump Inhibitors - therapeutic use ; Quality Improvement ; quality improvement activity ; Quinine - therapeutic use ; Renal Dialysis ; Tertiary Care Centers</subject><ispartof>American journal of kidney diseases, 2017-11, Vol.70 (5), p.611-618</ispartof><rights>National Kidney Foundation, Inc.</rights><rights>2017 National Kidney Foundation, Inc.</rights><rights>Copyright © 2017 National Kidney Foundation, Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c477t-10a335b59da63bafc4ebc345cf646c169a486ad6af62ab1257587e502c69f9f73</citedby><cites>FETCH-LOGICAL-c477t-10a335b59da63bafc4ebc345cf646c169a486ad6af62ab1257587e502c69f9f73</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1053/j.ajkd.2017.02.374$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28416321$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>McIntyre, Caitlin, Pharm D</creatorcontrib><creatorcontrib>McQuillan, Rory, MD, MSc</creatorcontrib><creatorcontrib>Bell, Chaim, MD, PhD</creatorcontrib><creatorcontrib>Battistella, Marisa, Pharm D</creatorcontrib><title>Targeted Deprescribing in an Outpatient Hemodialysis Unit: A Quality Improvement Study to Decrease Polypharmacy</title><title>American journal of kidney diseases</title><addtitle>Am J Kidney Dis</addtitle><description>Background Polypharmacy in hemodialysis patients can result in adverse patient outcomes. Deprescribing tools can reduce polypharmacy, yet no method exists for an outpatient hemodialysis population. Design Quality improvement study. Setting &amp; Participants 240 patients in a tertiary-care outpatient hemodialysis unit. Quality Improvement Plan We aimed to: (1) develop a deprescribing tool for target medications with poor evidence for efficacy and safety, (2) determine its effectiveness in decreasing polypharmacy, and (3) monitor patient safety and satisfaction. Outcomes The primary outcome was the proportion of target medications completely deprescribed after 4 weeks. Secondary outcomes were the proportion of target medications completely deprescribed after 6 months, average number of medications per patient before and after deprescription, and proportion of successful deprescriptions for each target medication. Measurements Number of medications deprescribed at 4 weeks and 6 months. Patient safety and satisfaction were monitored using drug-specific monitoring parameters. Results A deprescribing tool for specific medications was developed and implemented in the hemodialysis unit. 5 medication classes were selected: quinine, diuretics, α1 -blockers, proton pump inhibitors, and 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins). All 240 patients in the unit were screened using the deprescribing tool. There were 171 of 240 (71%) patients prescribed at least 1 of the 5 target medications, and after applying the tool, 35 of 40 (88%) eligible patients had the medications deprescribed. There were 31 of 40 (78%) target medications completely deprescribed. 6 months after the study, only 5 of 31 (16%) medications discontinued were represcribed. At the end of the study, 57% of patients were taking fewer medications than at baseline. No adverse events were observed. Limitations Single-center study that relied on patient self-reporting of medication use and adherence to our recommendations. Conclusions Deprescribing tools can be applied successfully in an outpatient hemodialysis unit to reduce polypharmacy while maintaining patient safety and satisfaction.</description><subject>Adrenergic alpha-Antagonists - therapeutic use</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Ambulatory Care</subject><subject>Deprescribing</subject><subject>Deprescriptions</subject><subject>Diuretics - therapeutic use</subject><subject>elderly</subject><subject>end-stage renal disease (ESRD)</subject><subject>Female</subject><subject>hemodialysis (HD)</subject><subject>Hemodialysis Units, Hospital</subject><subject>Humans</subject><subject>Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use</subject><subject>Kidney Failure, Chronic - therapy</subject><subject>Male</subject><subject>medication optimization</subject><subject>medication prescribing patterns</subject><subject>Middle Aged</subject><subject>Muscle Relaxants, Central - therapeutic use</subject><subject>Nephrology</subject><subject>Ontario</subject><subject>outpatient HD</subject><subject>patient safety</subject><subject>pill burden</subject><subject>Polypharmacy</subject><subject>potentially inappropriate medications</subject><subject>Proton Pump Inhibitors - therapeutic use</subject><subject>Quality Improvement</subject><subject>quality improvement activity</subject><subject>Quinine - therapeutic use</subject><subject>Renal Dialysis</subject><subject>Tertiary Care Centers</subject><issn>0272-6386</issn><issn>1523-6838</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kctu1TAQhi0EoofCC7BAXrJJ8CVxHISQqnJppUoFtV1bE2dSfJpbbadS3oZn4clwdAoLFqw8i-__Nf6GkNec5ZyV8t0-h_1dmwvGq5yJXFbFE7LjpZCZ0lI_JTsmKpEpqdUReRHCnjFWS6WekyOhC66k4DsyX4O_xYgt_YSzx2C9a9x4S91IYaSXS5whOhwjPcNhah30a3CB3owuvqcnv35-X6B3caXnw-ynBxw28iou7UrjlBqtRwhIv039Ov8AP4BdX5JnHfQBXz2-x-Tmy-fr07Ps4vLr-enJRWaLqooZZyBl2ZR1C0o20NkCGyuL0naqUJarGgqtoFXQKQENF2VV6gpLJqyqu7qr5DF5e-hNi90vGKIZXLDY9zDitATDta6TGVbrhIoDav0UgsfOzN4N4FfDmdlMm73ZTJvNtGHCJNMp9Oaxf2kGbP9G_qhNwIcDgOmXDw69CTaZtNg6jzaadnL_7__4T9z2bnQW-jtcMeynxY_Jn-EmCMPM1Xbr7dS8kqzUafwNBlGmdw</recordid><startdate>20171101</startdate><enddate>20171101</enddate><creator>McIntyre, Caitlin, Pharm D</creator><creator>McQuillan, Rory, MD, MSc</creator><creator>Bell, Chaim, MD, PhD</creator><creator>Battistella, Marisa, Pharm D</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20171101</creationdate><title>Targeted Deprescribing in an Outpatient Hemodialysis Unit: A Quality Improvement Study to Decrease Polypharmacy</title><author>McIntyre, Caitlin, Pharm D ; McQuillan, Rory, MD, MSc ; Bell, Chaim, MD, PhD ; Battistella, Marisa, Pharm D</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c477t-10a335b59da63bafc4ebc345cf646c169a486ad6af62ab1257587e502c69f9f73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Adrenergic alpha-Antagonists - therapeutic use</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Ambulatory Care</topic><topic>Deprescribing</topic><topic>Deprescriptions</topic><topic>Diuretics - therapeutic use</topic><topic>elderly</topic><topic>end-stage renal disease (ESRD)</topic><topic>Female</topic><topic>hemodialysis (HD)</topic><topic>Hemodialysis Units, Hospital</topic><topic>Humans</topic><topic>Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use</topic><topic>Kidney Failure, Chronic - therapy</topic><topic>Male</topic><topic>medication optimization</topic><topic>medication prescribing patterns</topic><topic>Middle Aged</topic><topic>Muscle Relaxants, Central - therapeutic use</topic><topic>Nephrology</topic><topic>Ontario</topic><topic>outpatient HD</topic><topic>patient safety</topic><topic>pill burden</topic><topic>Polypharmacy</topic><topic>potentially inappropriate medications</topic><topic>Proton Pump Inhibitors - therapeutic use</topic><topic>Quality Improvement</topic><topic>quality improvement activity</topic><topic>Quinine - therapeutic use</topic><topic>Renal Dialysis</topic><topic>Tertiary Care Centers</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>McIntyre, Caitlin, Pharm D</creatorcontrib><creatorcontrib>McQuillan, Rory, MD, MSc</creatorcontrib><creatorcontrib>Bell, Chaim, MD, PhD</creatorcontrib><creatorcontrib>Battistella, Marisa, Pharm D</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>American journal of kidney diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>McIntyre, Caitlin, Pharm D</au><au>McQuillan, Rory, MD, MSc</au><au>Bell, Chaim, MD, PhD</au><au>Battistella, Marisa, Pharm D</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Targeted Deprescribing in an Outpatient Hemodialysis Unit: A Quality Improvement Study to Decrease Polypharmacy</atitle><jtitle>American journal of kidney diseases</jtitle><addtitle>Am J Kidney Dis</addtitle><date>2017-11-01</date><risdate>2017</risdate><volume>70</volume><issue>5</issue><spage>611</spage><epage>618</epage><pages>611-618</pages><issn>0272-6386</issn><eissn>1523-6838</eissn><abstract>Background Polypharmacy in hemodialysis patients can result in adverse patient outcomes. Deprescribing tools can reduce polypharmacy, yet no method exists for an outpatient hemodialysis population. Design Quality improvement study. Setting &amp; Participants 240 patients in a tertiary-care outpatient hemodialysis unit. Quality Improvement Plan We aimed to: (1) develop a deprescribing tool for target medications with poor evidence for efficacy and safety, (2) determine its effectiveness in decreasing polypharmacy, and (3) monitor patient safety and satisfaction. Outcomes The primary outcome was the proportion of target medications completely deprescribed after 4 weeks. Secondary outcomes were the proportion of target medications completely deprescribed after 6 months, average number of medications per patient before and after deprescription, and proportion of successful deprescriptions for each target medication. Measurements Number of medications deprescribed at 4 weeks and 6 months. Patient safety and satisfaction were monitored using drug-specific monitoring parameters. Results A deprescribing tool for specific medications was developed and implemented in the hemodialysis unit. 5 medication classes were selected: quinine, diuretics, α1 -blockers, proton pump inhibitors, and 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins). All 240 patients in the unit were screened using the deprescribing tool. There were 171 of 240 (71%) patients prescribed at least 1 of the 5 target medications, and after applying the tool, 35 of 40 (88%) eligible patients had the medications deprescribed. There were 31 of 40 (78%) target medications completely deprescribed. 6 months after the study, only 5 of 31 (16%) medications discontinued were represcribed. At the end of the study, 57% of patients were taking fewer medications than at baseline. No adverse events were observed. Limitations Single-center study that relied on patient self-reporting of medication use and adherence to our recommendations. Conclusions Deprescribing tools can be applied successfully in an outpatient hemodialysis unit to reduce polypharmacy while maintaining patient safety and satisfaction.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>28416321</pmid><doi>10.1053/j.ajkd.2017.02.374</doi><tpages>8</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0272-6386
ispartof American journal of kidney diseases, 2017-11, Vol.70 (5), p.611-618
issn 0272-6386
1523-6838
language eng
recordid cdi_proquest_miscellaneous_1889386098
source MEDLINE; Elsevier ScienceDirect Journals Complete
subjects Adrenergic alpha-Antagonists - therapeutic use
Adult
Aged
Aged, 80 and over
Ambulatory Care
Deprescribing
Deprescriptions
Diuretics - therapeutic use
elderly
end-stage renal disease (ESRD)
Female
hemodialysis (HD)
Hemodialysis Units, Hospital
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use
Kidney Failure, Chronic - therapy
Male
medication optimization
medication prescribing patterns
Middle Aged
Muscle Relaxants, Central - therapeutic use
Nephrology
Ontario
outpatient HD
patient safety
pill burden
Polypharmacy
potentially inappropriate medications
Proton Pump Inhibitors - therapeutic use
Quality Improvement
quality improvement activity
Quinine - therapeutic use
Renal Dialysis
Tertiary Care Centers
title Targeted Deprescribing in an Outpatient Hemodialysis Unit: A Quality Improvement Study to Decrease Polypharmacy
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T01%3A28%3A31IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Targeted%20Deprescribing%20in%20an%20Outpatient%20Hemodialysis%20Unit:%20A%C2%A0Quality%20Improvement%20Study%20to%20Decrease%20Polypharmacy&rft.jtitle=American%20journal%20of%20kidney%20diseases&rft.au=McIntyre,%20Caitlin,%20Pharm%20D&rft.date=2017-11-01&rft.volume=70&rft.issue=5&rft.spage=611&rft.epage=618&rft.pages=611-618&rft.issn=0272-6386&rft.eissn=1523-6838&rft_id=info:doi/10.1053/j.ajkd.2017.02.374&rft_dat=%3Cproquest_cross%3E1889386098%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1889386098&rft_id=info:pmid/28416321&rft_els_id=S0272638617305826&rfr_iscdi=true